脏变质减轻了自发高血压大鼠的血管改造,通过调节周围血管脂肪组织
Tingting Jiang1, Yongkang Wei1, Rui Xu1
1Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
概括
脏缩 (RDN) 通过改变周围血管脂肪组织 (PVAT) 来减少高血压血管重塑. 通过调节PVAT特征和相关蛋白质表达,RDN可能会改善心血管健康.
科学领域:
- 心血管科学 心血管科学
- 高血压研究 高血压研究
- 脂肪组织生物学 脂肪组织生物学
背景情况:
- 高血压诱导的目标器官损伤主要是由血管重塑驱动的.
- 周血管脂肪组织 (PVAT) 对心血管疾病的发病有显著的贡献.
- 了解PVAT在高血压中的作用对于开发有效的治疗方法至关重要.
研究的目的:
- 为了研究脏缩 (RDN) 对高血压血管改造的影响.
- 阐明PVAT在RDN和高血压的背景下的特定作用.
- 探索RDN影响PVAT的分子机制.
主要方法:
- 使用自发高血压大鼠 (SHR) 和Wistar-Kyoto (WKY) 的大鼠.
- 通过H&E和Mason的三色染色来评估大动脉血管改造.
- 分析了PVAT形态 (H&E,油红色O),氧化应激 (二乙) 和蛋白质表达 (西方斑).
主要成果:
- 与WKY相比,SHR表现出大动脉中枢厚度,原蛋白和PVAT氧化应激增加.
- 在SHR中的RDN (SHR-RDN) 显著降低了这些重塑标记物和PVAT氧化应激.
- RDN诱导了PVAT色,增加了UCP-1和Nrg4的表达,并改变了阿迪波内克丁/莱普丁水平.
结论:
- 在老鼠中,RDN有效地减轻了高血压的血管重塑.
- 这些有益影响与PVAT特征和功能的显著调节有关.
- 通过向PVAT介导的途径,RDN代表了高血压的潜在治疗策略.
更多相关视频
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
589
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
589
01:25Antihypertensive Drugs: Direct Renin Inhibitors
528
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
528
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
683
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
683
01:23Antihypertensive Drugs: Vasodilators
495
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
495
01:18Hypertension and Regulation of Blood Pressure
2.0K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K